In this Issue:
CSF NFL as a biomarker in MS
MRI pattern in natalizumab-associated PML
Fingolimod first-dose effects in relapsing MS patients receiving SSRIs
BREMSO: A simple score to predict MS evolution
Prognostic factors for developing MS
Conversion from CIS to MS
Switching from natalizumab to fingolimod in RRMS
Peginterferon beta-1a in MS
Safety and tolerability of glatiramer acetate 40 mg three-times weekly vs 20 mg daily for RRMS
Fatigue in patients with CIS and its association with CDMS diagnosis
Please login below to download this issue (PDF)